Qualigen Therapeutics Stock (NASDAQ:QLGN)
Previous Close
$2.90
52W Range
$2.73 - $13.45
50D Avg
$3.56
200D Avg
$4.06
Market Cap
$4.58M
Avg Vol (3M)
$838.51K
Beta
0.03
Div Yield
-
QLGN Company Profile
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.